GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: ORIC114
Compound class:
Synthetic organic
Comment: ORIC-114 is an advanced, orally bioavailable, brain penetrant EGFR and ERBB2 (HER2) inhibitor that is designed to target these receptor tyrosine kinases with oncogenic exon 20 insertion mutations in metastatic non-small-cell lung cancer and other similarly mutated solid tumours [1].
|
|
No information available. |
Summary of Clinical Use ![]() |
ORIC-114 is a clinical candidate for the treatment of solid tumours with EGFR or HER2 exon 20 insertion mutations. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05315700 | Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Phase 1/Phase 2 Interventional | ORIC Pharmaceuticals | ||
NCT06816992 | ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC | Phase 1 Interventional | ORIC Pharmaceuticals |